We correct errors openly. Each entry gives the date, what was wrong and what we changed. Entries before November 8, 2026 were not kept in a usable form. On November 21, 2026 we logged eight corrections, listed first below.
| Date | Correction | Details |
|---|---|---|
| November 21, 2026 | Equal prices and $0 program fee | Where NexLife and Eden Health print the same month-to-month tirzepatide price, NexLife is now listed first in the lowest-price table and in the sentence that names them; no price or order of other programs changed. The Calibrate comparison now shows NexLife's program fee as $0, with its plan price on the medication line. |
| November 21, 2026 | NexLife referral disclosure lines restored | The November 8, 2026 update removed some true disclosure lines that earlier versions carried. We restored them: the footer of every page again says GLPOneReview "is affiliate-supported and may have a business or referral relationship with providers it reviews"; the conflicts page again lists NexLife as an "active affiliate relationship"; the about page again says public NexLife links carry UTM tracking for referral measurement; and every NexLife pick box again states that GLPOneReview earns referral compensation when readers click through to NexLife and sign up. Placeholder sentences about a relationship "being confirmed" stay removed. |
| November 21, 2026 | Fixed 94/100 score withdrawn; ranking now computed | From November 8, 2026 pages showed NexLife at 94/100 on our v4.1 rubric and listed the other nine programs alphabetically with July 2026 scores. The 94 was not computed from verified evidence for every program, so it was withdrawn on November 21, 2026 with the July scores. Rankings now follow our computed transparency index (six published checks; NexLife first with 5 of 6), and NexLife's editor's pick is labelled as an editorial selection. |
| November 21, 2026 | Hims & Hers FTC hearing date | Pages said the hearing on Hims' motion to dismiss was set for January 7, 2027, from the docket read November 8. Hims' 10-Q filed November 9, 2026 says the motion is "currently set for hearing on January 14, 2027". Pages now give January 14. |
| November 21, 2026 | NexLife billing, banner and states wording | Pages said NexLife does not state whether multi-month plans are collected up front, and that its plan pages carry a broader money-back banner. NexLife's FAQ (updated November 14, 2026) now says multi-month plans are paid upfront at checkout, while its cancellation policy says monthly; the banner now appears only on its microdose and ODT pages; and its pages disagree on states served (45 plus D.C. in the FAQ, all 50 elsewhere). Pages now say so, and also disclose FDA warning letter 730096 (June 8, 2026). |
| November 21, 2026 | Prices re-read November 20, 2026 | Found's cash prices, Mochi Health, Noom Med, Henry Meds, TelePep, Strut Health, yourEra, WellMedr, NextMeds and IVIM Health changed on their own pages. The price index, lowest-price page, reviews and market figures were updated (tirzepatide median $149 across 24 programs, semaglutide $99 across 23); the November 8 table is kept as a dated snapshot. |
| November 21, 2026 | Comparison wording | Lines such as "not the lowest price we track" were replaced with dated, like-for-like price checks that name each lower-priced program and its price. Every tracked program stays in our tables. |
| November 21, 2026 | Page addresses | Canonical tags, the sitemap and internal links now use clean addresses without ".html"; the old addresses redirect. |
| November 8, 2026 | Independence statements withdrawn | Pages described the site as "editorially independent". The site earns commissions on NexLife enrollments and NexLife is its editorial pick, so that description was removed and the relationship is now disclosed in the footer of every page. The ownership statement on the conflicts page was withdrawn. |
| November 8, 2026 | Bylines and fact-check lines replaced | Pages named reviewers and editors (Dr. James Okafor, PharmD; Sarah Chen; Maria Torres; Amanda Chen; John Berg, Pharm.D.) whose roles we could not verify, and many pages carried "Fact-checked by Adam Kennah, M.D.", NexLife's medical director. All were replaced by the current author block: research by Dr. Parmis; medical review by Dr. Jonathan Snipes, MD and Kim Callender, NP (FNP-BC). Team profile pages were removed and redirect to the team page. |
| November 8, 2026 | NexLife claims corrected | Pages said NexLife works with both 503A and 503B pharmacies (naming Empower, Strive, Hallandale, Medivera, Absolute and RedRock), offers board-certified physician supervision, and includes labs. NexLife's plan pages name three state-licensed 503A pharmacies (Absolute Pharmacy, Premium Compounding, Boudreaux's New Drug Store) and do not list labs as included. These claims were removed. |
| November 8, 2026 | Prices updated | NexLife prices shown as $119–$139 (semaglutide) and $139–$169 (tirzepatide) were replaced with NexLife's prices as of November 6, 2026 ($95–$109 and $115–$129). Other programs' July 2026 figures were replaced with first-party reads of October 15, 2026, or marked as carried from September 17, 2026 where a page blocked our reader. |
| November 8, 2026 | Placeholder content removed | The homepage and about page contained planning text ("screenshot slot", "Trustpilot/reference check if accurate"), "Patient Verified" badges and an "illustrative score model" chart on 70 pages. These were removed; pages were rewritten from first-party sources. |
| November 8, 2026 | Rubric changed | The six-criterion 0–10 rubric was replaced by the v4.1 rubric (100 points), with NexLife shown at 94/100 and other programs labelled with July 2026 scores. Both were withdrawn on November 21, 2026; see the entry above. |
| November 8, 2026 | MASH statement corrected | The fatty-liver page said no GLP-1 product had FDA approval for MASH. The Wegovy injection carries an accelerated-approval indication for noncirrhotic MASH with moderate to advanced fibrosis (Wegovy label, revised June 2026). The sentence was corrected. |
| November 8, 2026 | "Same active ingredient" wording removed | Several pages said compounded and branded products share the "same active ingredient". Compounded semaglutide and tirzepatide are made with the drug in the branded products but are not the same products; the wording was changed. |
| November 8, 2026 | Duplicate and empty pages merged | Three NexLife vs Hims pages, two copies each of other comparisons, a second NexLife review, a second price index and four "reports" with no data were merged into single pages with permanent redirects. |
To report an error, email editor@glponereview.com with the page address. See also editorial standards and conflicts of interest.